The trial aims to evaluate the safety and tolerability of TrasGEX, a glycooptimized HER2 biobetter antibody.
TrasGEX is developed using GlycoExpress, the company’s development and production platform based on glycoengineered human cell lines for biopharmaceuticals with fully human and optimized glycosylation.
Glycotope CEO, CSO and founder Steffen Goletz said after CetuGEX and PankoMab-GEX, TrasGEX is their third anti-cancer antibody which entered clinical trials in time.
"Our glycooptimized Follicle-Stimulating Hormone FSH-GEX has already completed clinical Phase Ia with very exciting results," Goletz said.